MeiraGTx Holdings plc(MGTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 18.21 | EPS (ttm) | 0.71 | Insider Own | 24.2% | Shs Outstand | 94.2M | Perf Week | -8.61% |
| Market Cap | 1.23B | Forward P/E | - | EPS next Y | -647.64% | Insider Trans | -1.5% | Shs Float | 72.8M | Perf Month | -1.53% |
| Enterprise Value | 1.20B | PEG | - | EPS next Q | -0.5 | Inst Own | 63% | Short Float | 5.14% | Perf Quarter | 40.59% |
| Income | 0.08B | P/S | 3.1 | EPS this Y | 122.03% | Inst Trans | 11.96% | Short Ratio | 4.43 | Perf Half Y | 64.53% |
| Sales | 0.40B | P/B | 5.61 | EPS next 5Y | -1.01% | ROA | 26.54% | Short Interest | 3.74M | Perf YTD | 61.64% |
| Book/sh | 2.29 | P/C | 8.62 | EPS past 3/5Y | 20.9% 1.58% | ROE | 72.28% | 52W High | -16.29% ($15.35) | Perf Year | 71.56% |
| Cash/sh | 1.49 | P/FCF | 117.88 | Sales past 3/5Y | 72.27% 39.22% | ROIC | 24.26% | 52W Low | 94.11% ($6.62) | Perf 3Y | 132.37% |
| Dividend Est. | - | EV/EBITDA | 6.18 | EPS Y/Y TTM | 136.8% | Gross Margin | 94.9% | Volatility(W/M) | 4.23% 5.38% | Perf 5Y | 6.82% |
| Dividend TTM | - | EV/Sales | 3.03 | Sales Y/Y TTM | 948.35% | Oper. Margin | 45.94% | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.76 | EPS Q/Q | 455.9% | Profit Margin | 19.87% | RSI (14) | 40.89 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.76 | Sales Q/Q | 8608.59% | SMA20 | -8.06% ($13.98) | Beta | 1.33 | Target Price | $29.43 |
| Payout | - | Debt/Eq | 0.52 | Earnings | 2026/8/13 | SMA50 | -2.69% ($13.21) | Rel Volume | 0.85 | Prev Close | $13.26 |
| Employees | 403 | LT Debt/Eq | 0.51 | EPS/Sales Surpr. | 473.12% 45819.14% | SMA200 | 31.09% ($9.8) | Avg Volume(3M) | 0.84M | Price | $12.85 |
| IPO | 2018/6/8 | Option/Short | Yes/Yes | Trades | 7988 | Volume | 715,221 | Change | -3.09% |
Company
MGTX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 MeiraGTx Holdings (ticker: MGTX) is a vertically integrated, clinical-stage biotechnology company developing gene therapies targeting ophthalmic and central nervous system diseases. The company is distinguished by its adeno-associated virus (AAV) vector-based therapies, its proprietary riboswitch platform for regulating gene expression, and its in-house manufacturing capabilities. It is building a late-stage clinical pipeline aimed at addressing unmet medical needs in rare genetic diseases.
Over the past 1 year, roughly in the middle
16% below its 1-year high.
MGTX makes money exceptionally well
45.94% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +122.0% this year.
Tap to view numbers
The stock looks undervalued
Trading at 18.2 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +132.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 63.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBC 0.01%
QQQS 0.01%
IWC 0.00%
KOMP 0.00%
ESSC 0.00%It ranks #4 in the industry
Based on market cap of $1B.
MGTX $1B PER 18.2
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is MGTX?
MGTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MGTX?
The market cap of MGTX is approximately $1.2B, ranking 2,479 within its sector.
What is the P/E ratio of MGTX?
MGTX has a P/E ratio of approximately 18.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MGTX?
MGTX has recorded a 52-week high of $15.35 and a low of $6.62.
